| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,023 | 0,035 | 11:16 |
Trading in Active Biotech AB (publ)s paid subscription shares is to cease. The last trading day is December 19, 2023 Short name: ACTI BTA --------------------------- ISIN code: SE0021021920 --------------------------- Orderbook ID: 311861 --------------------------- This information is distributed at the request of Active Biotech AB (publ). For further information, please call Helén Tuvesson, CEO at Active Biotech AB (publ) on +46 46 19 21 56.
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 24.10. | XFRA CAPITAL ADJUSTMENT INFORMATION - 24.10.2024 | Das Instrument EGID FR0000072373 EGIDE S.A. INH. EO 2 EQUITY wird cum Kapitalmassnahme gehandelt am 24.10.2024 und ex Kapitalmassnahme am 25.10.2024 The instrument EGID FR0000072373 EGIDE S.A. INH.... ► Artikel lesen | |
| 21.10. | Active Biotech AB: Active Biotech Interim Report Q3 2024 | THIRD QUARTER IN BRIEFActive Biotech entered agreement with MD Anderson for a clinical study of tasquinimod in myelofibrosis (July 1)Active Biotech provided an update on the clinical phase Ib/IIa study... ► Artikel lesen | |
| 23.09. | Active Biotech AB: Active Biotech announces a rights issue of SEK 35 million | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE... ► Artikel lesen | |
| 10.09. | Active Biotech AB: Active Biotech reports intriguing intraocular concentrations achieved in a clinical biodistribution study of laquinimod eye drops | Lund, September 10 2024 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced an update to the ongoing clinical phase I biodistribution study of laquinimod eye drops in patients undergoing vitrectomy.
A... ► Artikel lesen | |
| 22.08. | Active Biotech AB: Active Biotech Interim Report Q2 2024 | SECOND QUARTER IN BRIEFStart of enrollment to the clinical phase I biodistribution study with laquinimod eye drops (April 3)Active Biotech acquired exclusive rights to patents of tasquinimod in combination... ► Artikel lesen |
